Reliant Will Launch Pronova's Omacor In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Reliant will maintain the NDA for Omacor (omega-3 acid ethyl esters) and its sales force will be the sole U.S. marketer of the hypertriglyceridemia treatment. Abbott's Ross Products division filed the original NDA, as well as a separate application FDA has deemed "approvable."
You may also be interested in...
Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.
Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.
Reliant Adds Antara To Cardiovascular Portfolio Following Approval
Antara (fenofibrate) clears FDA under Sec. 505(b)(2) NDA provision; it will compete with Abbott's Tricor to treat adult patients with primary hypercholesterolemia, mixed dyslipidemia, or hypertriglyceridemia. Abbott is developing a new formulation of Tricor.